Trial Profile

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lapatinib (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; Male breast cancer
Focus Adverse reactions

Most Recent Events

10 Jun 2025 Planned End Date changed from 22 Feb 2025 to 19 May 2026.
21 Jun 2021 Planned End Date changed from 20 Apr 2021 to 22 Feb 2025.
15 Dec 2020 Planned End Date changed from 1 Nov 2020 to 20 Apr 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com